Abstract
Serum concentrations of BGP, AP, IGF-1 and peak growth hormone (CH) after clonidine were studied in 10 girls and 2 boys, aged 6.2-8.7 years, with central PP during treatment with a combination of LHRH analogue and cyproterone-acetate (CA) for 1.5-2.5 years. Linear growth declined from 11.3 ± 0.6 cm/year (mean±SEM) to 6.0 ± 0.6 in the first 6 months of therapy and further to 3.7 ± 0.6 after 2.5 years. Serum BGP levels were elevated prior to therapy compared with age-matched children (p<0.001). During the first 6 months of treatment serum BGP decreased (p<0.05) but then showed a significant increase (p<0.01) during the following 2 years to levels not different from pretreatment values. Serum AP decreased throughout the study especially in the first 6 months (p<0.001). Peak serum GH values decreased (p<0.05) after initiation of therapy, whereas serum IGF-1 remained significantly elevated (p<0.00l) for age. In normal puberty serum levels of BGP and AP reflect bone formation and these parameters together with IGF-1 increase during the skeletal growth spurt. In this study serum AP seems to reflect the declining linear growth rate concomitant with an increase in serum BGP. Thus our data indicate a different bone turnover in PP during treatment with LHRH analogue and CA.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Thøger Nielsen, C., Krabbe, S., Johansen, J. et al. 138 ADVERSE CHANCES IN SERUM BONE GLA-PROTEIN (BGP) AND ALKALINE PHOSPHATASE (AP) IN PRECOCIOUS PUBERTY (PP) DURING THERAPY. Pediatr Res 24, 540 (1988). https://doi.org/10.1203/00006450-198810000-00159
Issue Date:
DOI: https://doi.org/10.1203/00006450-198810000-00159